Other News To Note
Thursday, April 14, 2011
Seattle Genetics Inc., of Bothell, Wash., announced that 10 programs using the company's antibody-drug conjugate (ADC) technology are now in clinical development across its 11 current ADC collaborations. That includes two additional ADC programs for which investigational new drug applications were recently submitted to the FDA by Genentech, a member of the Roche Group, of Basel, Switzerland, triggering milestone payments to Seattle Genetics.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.